earnings
confidence high
sentiment neutral
materiality 0.75
C4 Therapeutics Q1 net loss $26.3M; cemsidomide 50% ORR at 100 µg in MM
C4 Therapeutics, Inc.
2025-Q1 EPS reported
-$0.37
revenue$7,238,000
- Revenue $7.2M (up from $3.0M YoY); net loss $0.37/share vs $0.41.
- Cemsidomide Phase 1 MM dose escalation complete; 100 µg QD safe for expansion; ORR 50% at 100 µg, 40% at 75 µg.
- One patient achieved MRD-negative complete response after prior T-cell engager therapies.
- Will not advance CFT1946 beyond Phase 1; seeking partnership for BRAF program.
- Cash $234.7M, runway into 2027; earned $4M from two Roche preclinical milestones.